What Is Retatrutide?

<p>What is retatrutide, how does it work, and what do the latest retatrutide clinical trial results actually mean for people living with obesity?</p><p>In this episode of <em>Weight &amp; Measure with Mike and Zach</em>, Dr. Ania Jastreboff and Ted Kyle join Mike Donnelly-Boylen and Zach Niemiec for a patient-centered deep dive into retatrutide, the investigational GLP-1/GIP/glucagon triple agonist being studied for obesity and type 2 diabetes.</p><p>Dr. Jastreboff is a Yale physician-scientist, a leading obesity researcher, and has been deeply involved in the clinical development of retatrutide. She presented the first Phase 3 obesity results from TRIUMPH-1 at the American Diabetes Association Scientific Sessions and is co-author of <em>Enough</em> with Oprah Winfrey.</p><p>Ted Kyle is a pharmacist and longtime obesity advocate who brings together obesity science, policy, advocacy and lived experience.</p><p>Dr. Jastreboff explains how GLP-1, GIP and glucagon work, why researchers combined all three receptors into one medication, and why activating the glucagon receptor may make sense even though glucagon is commonly associated with increasing blood glucose.</p><p>We then break down the TRIUMPH-1 retatrutide results, including:</p><p>• How much weight participants lost with retatrutide<br>• Why results may differ between obesity and type 2 diabetes<br>• Retatrutide doses, titration, side effects and discontinuation<br>• Whether everyone needs the highest retatrutide dose<br>• How clinical-trial dosing differs from real-world obesity treatment</p><p>We tackle one of the biggest questions surrounding GLP-1 medications: muscle loss.</p><p>Dr. Jastreboff explains the important difference between lean mass and skeletal muscle, what body-composition studies can actually measure, and what we know so far about retatrutide compared with semaglutide and tirzepatide.</p><p>The conversation goes beyond the number on the scale to explore findings involving knee osteoarthritis, obstructive sleep apnea, liver fat, metabolic health and other complications of obesity.</p><p>We also ask whether comparing retatrutide vs tirzepatide vs metabolic &amp; bariatric surgery misses the bigger point. Could the future of obesity care involve choosing and combining treatments based on the individual rather than asking which treatment “wins”?</p><p>Ted explains Lilly’s planned Biologics License Application (BLA) for retatrutide, what biologic status could mean for future competition a